

Sook-Hyang Jeong

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/4749447/publications.pdf>

Version: 2024-02-01

111
papers

2,274
citations

236925

25
h-index

289244

40
g-index

118
all docs

118
docs citations

118
times ranked

2952
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. <i>Liver International</i> , 2022, 42, 320-329.	3.9	7
2	A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 91-104.	8.9	10
3	A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis. <i>Scientific Reports</i> , 2022, 12, 1717.	3.3	1
4	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. <i>Hepatology International</i> , 2022, 16, 1-23.	4.2	45
5	Effectiveness of 4-Week Oral Taurine Treatment for Muscle Cramps in Patients with Liver Cirrhosis: A Single-Arm Pilot Study. <i>Yonsei Medical Journal</i> , 2021, 62, 21.	2.2	8
6	Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4536-4544.	2.3	1
7	Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection. <i>Translational Cancer Research</i> , 2021, 10, 854-866.	1.0	18
8	Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S1-S8.	1.7	4
9	Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study. <i>Cut and Liver</i> , 2021, 15, 295-306.	2.9	4
10	Environmental risk factors and comorbidities of primary biliary cholangitis in Korea: a case-control study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 313-321.	1.7	6
11	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. <i>Cut and Liver</i> , 2021, 15, 895-903.	2.9	3
12	Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4453-4467.	3.3	8
13	The Role of Urinary N-Acetyl- β -D-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4328.	2.4	6
14	Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in South Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID. <i>Epidemiology and Health</i> , 2021, , e2021077.	1.9	2
15	Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. <i>JHEP Reports</i> , 2020, 2, 100175.	4.9	20
16	Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1774-1781.	2.8	20
17	A case of acute liver failure due to hepatitis E virus, liver transplantation, and development of de novo autoimmune hepatitis. <i>Transplant Infectious Disease</i> , 2020, 22, e13287.	1.7	2
18	A Case of Autoimmune Hepatitis after Occupational Exposure to N,N-Dimethylformamide. <i>Journal of Korean Medical Science</i> , 2020, 35, e228.	2.5	4

#	ARTICLE	IF	CITATIONS
19	The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 492-505.	8.9	39
20	Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. <i>Gut and Liver</i> , 2020, 14, 207-217.	2.9	18
21	Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. <i>Gut and Liver</i> , 2020, 14, 775-782.	2.9	6
22	A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. <i>Gut and Liver</i> , 2020, 14, 808-816.	2.9	9
23	1605. Differences in Clinical Characteristics of Third Generation Cephalosporin Resistance and Treatment Outcomes in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Bacteremia in Patients with Liver Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2020, 7, S798-S798.	0.9	0
24	Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population. <i>Liver International</i> , 2019, 39, 60-69.	3.9	12
25	MicroRNA-20 induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells. <i>Molecular Medicine Reports</i> , 2019, 20, 2285-2293.	2.4	6
26	The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015. <i>Hepatology International</i> , 2019, 13, 599-608.	4.2	16
27	Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test. <i>Journal of Medical Virology</i> , 2019, 91, 2158-2165.	5.0	1
28	ABO-incompatible liver transplantation using only rituximab for patients with low anti-ABO antibody titer. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2019, 23, 211.	0.1	4
29	Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. <i>PLoS ONE</i> , 2019, 14, e0212771.	2.5	20
30	A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. <i>Hepatology</i> , 2019, 70, 621-629.	7.3	23
31	Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 776-783.	2.8	0
32	Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1233-1243.	1.7	10
33	Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1357-1369.	3.0	7
34	Natural History, Clinical Manifestations, and Pathogenesis of Hepatitis A. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031708.	6.2	84
35	Hepatic iron overload in the portal tract predicts poor survival in hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2018, 38, 903-914.	3.9	9
36	Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D. <i>Gut and Liver</i> , 2018, 12, 440-448.	2.9	23

#	ARTICLE	IF	CITATIONS
37	Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A). Korean Journal of Radiology, 2018, 19, 1130.	3.4	7
38	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.	2.5	13
39	Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis. Journal of Digestive Diseases, 2018, 19, 605-613.	1.5	4
40	Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. PLoS ONE, 2018, 13, e0190261.	2.5	5
41	Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report. Clinical and Molecular Hepatology, 2018, 24, 163-168.	8.9	20
42	Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clinical and Molecular Hepatology, 2018, 24, 10-19.	8.9	19
43	The Clinicopathological and Prognostic Significance of the Gross Classification of Hepatocellular Carcinoma. Journal of Pathology and Translational Medicine, 2018, 52, 85-92.	1.1	25
44	Isolation of hepatitis E virus genotype 4 from patients with acute cryptogenic hepatitis in Korea. Journal of Clinical Virology, 2017, 89, 10-13.	3.1	17
45	Urgency to treat patients with chronic hepatitis C in Asia. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 966-974.	2.8	23
46	Occupational blood exposures in health care workers: incidence, characteristics, and transmission of bloodborne pathogens in South Korea. BMC Public Health, 2017, 17, 827.	2.9	38
47	Nationwide Seropositivity of Hepatitis A in Republic of Korea from 2005 to 2014, before and after the Outbreak Peak in 2009. PLoS ONE, 2017, 12, e0170432.	2.5	18
48	Persistent α -Fetoprotein Elevation in Healthy Adults and Mutational Analysis of α -Fetoprotein Promoter, Enhancer, and Silencer Regions. Gut and Liver, 2017, 11, 136-141.	2.9	11
49	Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS ONE, 2017, 12, e0182391.	2.5	38
50	Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget, 2017, 8, 106499-106510.	1.8	5
51	Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiology and Health, 2017, 39, e2017017.	1.9	25
52	Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea. Gut and Liver, 2017, 11, 426-433.	2.9	5
53	Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut and Liver, 2017, 11, 543-550.	2.9	7
54	Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data. Gut and Liver, 2017, 11, 835-842.	2.9	9

#	ARTICLE	IF	CITATIONS
55	Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study. Gut and Liver, 2017, 11, 270-275.	2.9	1
56	Comparative Analysis of Liver Injury-Associated Cytokines in Acute Hepatitis A and B. Yonsei Medical Journal, 2016, 57, 652.	2.2	6
57	Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. PLoS ONE, 2016, 11, e0158066.	2.5	12
58	Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver International, 2016, 36, 1067-1073.	3.9	39
59	Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea. Journal of Medical Virology, 2016, 88, 275-281.	5.0	8
60	Expression profile and prognostic value of glypican-3 in postoperative South Korean hepatocellular carcinoma patients. Apms, 2016, 124, 208-215.	2.0	15
61	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology International, 2016, 10, 947-955.	4.2	17
62	Hepatitis E. Vox Sanguinis, 2016, 110, 93-103.	1.5	48
63	Association between hepatitis C virus infection and Parkinson's disease. Movement Disorders, 2016, 31, 1584-1585.	3.9	23
64	The clinical outcomes of chronic hepatitis C in South Korea. Medicine (United States), 2016, 95, e4594.	1.0	5
65	Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0151069.	2.5	68
66	Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS ONE, 2016, 11, e0168189.	2.5	7
67	Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clinical and Molecular Hepatology, 2016, 22, 359-365.	8.9	23
68	Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 9427.	3.3	7
69	Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1281-1287.	2.8	17
70	Prediction of risk for hepatocellular carcinoma by response of serum α -fetoprotein to entecavir therapy. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1175-1182.	2.8	17
71	New direct-acting antivirals for the treatment of chronic hepatitis C. Journal of the Korean Medical Association, 2015, 58, 1154.	0.3	1
72	Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. Clinical and Molecular Hepatology, 2015, 21, 379.	8.9	17

#	ARTICLE	IF	CITATIONS
73	Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B. <i>Journal of Medical Virology</i> , 2015, 87, 993-998.	5.0	7
74	Prevalence and outcomes of extrahepatic primary malignancy associated with Hepatocellular Carcinoma in a Korean population. <i>BMC Cancer</i> , 2015, 15, 146.	2.6	6
75	Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). <i>PLoS ONE</i> , 2015, 10, e0138374.	2.5	1
76	Epidemiology of Hepatitis C Virus Infection in Korea. <i>Korean Journal of Medicine</i> , 2015, 88, 630.	0.3	9
77	Role of the PNPLA3 I148M Polymorphism in Nonalcoholic Fatty Liver Disease and Fibrosis in Korea. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2967-2974.	2.3	33
78	Treatment Outcomes of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma that Invades Hepatic Vein or Inferior Vena Cava. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1507-1515.	2.0	17
79	Geographic differences in the epidemiological features of HCV infection in Korea. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 361.	8.9	11
80	Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection. <i>Gut and Liver</i> , 2014, 8, 70-78.	2.9	6
81	Clinical and epidemiological features of hepatitis C virus infection in South Korea: A prospective, multicenter cohort study. <i>Journal of Medical Virology</i> , 2013, 85, 1724-1733.	5.0	65
82	Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: A nationwide, multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 128-134.	2.8	31
83	The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2013, 33, 1092-1099.	3.9	13
84	Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. <i>Journal of Medical Virology</i> , 2013, 85, 1327-1333.	5.0	36
85	A nationwide seroepidemiology of hepatitis C virus infection in South Korea. <i>Liver International</i> , 2013, 33, 586-594.	3.9	81
86	Body Mass Index as a Predictor of Advanced Colorectal Neoplasia. <i>Journal of Cancer Prevention</i> , 2013, 18, 144-148.	2.0	9
87	Seroprevalence of anti-hepatitis E virus (HEV) in a Korean population: comparison of two commercial anti-HEV assays. <i>BMC Infectious Diseases</i> , 2012, 12, 142.	2.9	53
88	Type and cause of liver disease in Korea: single-center experience, 2005-2010. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 309.	8.9	50
89	Behavioral and Healthcare-Associated Risk Factors for Chronic Hepatitis C Virus Infection in Korea. <i>Journal of Korean Medical Science</i> , 2012, 27, 1371.	2.5	18
90	Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study. <i>Gut and Liver</i> , 2012, 6, 98-106.	2.9	29

#	ARTICLE	IF	CITATIONS
91	The first case of genotype 4 hepatitis E related to wild boar in South Korea. Journal of Clinical Virology, 2011, 50, 253-256.	3.1	48
92	Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. Journal of Clinical Virology, 2011, 51, 241-245.	3.1	17
93	Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Very Elderly Patients. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2011, 57, 237.	0.4	8
94	Case report: A case of light chain deposition disease involving liver and stomach with chronic hepatitis C virus infection and hepatocellular carcinoma. Journal of Medical Virology, 2011, 83, 810-814.	5.0	7
95	Acute hepatitis C in Korea: Different modes of infection, high rate of spontaneous recovery, and low rate of seroconversion. Journal of Medical Virology, 2011, 83, 1195-1202.	5.0	11
96	Hepatitis A Virus genotype and its correlation with the clinical outcome of acute hepatitis A in Korea: 2006-2008. Journal of Medical Virology, 2011, 83, 2073-2081.	5.0	20
97	A nationwide seroprevalence of total antibody to hepatitis A virus from 2005 to 2009: age and area-adjusted prevalence rates. The Korean Journal of Hepatology, 2011, 17, 44.	1.5	20
98	Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. The Korean Journal of Hepatology, 2011, 17, 268.	1.5	10
99	Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report. The Korean Journal of Hepatology, 2011, 17, 323.	1.5	8
100	Current Status of Hepatitis E Virus Infection in Korea. Gut and Liver, 2011, 5, 427-431.	2.9	19
101	Atypical manifestations of hepatitis A infection: A prospective, multicenter study in Korea. Journal of Medical Virology, 2010, 82, 1318-1326.	5.0	48
102	Hepatitis A: Clinical Manifestations and Management. Intervirology, 2010, 53, 15-19.	2.8	166
103	An Epidemiologic Study on the Incidence and Significance of HFE Mutations in a Korean Cohort With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2010, 44, e154-e161.	2.2	13
104	Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease. The Korean Journal of Hepatology, 2010, 16, 288.	1.5	18
105	Hepatic Iron, Serum Ferritin, HFE Mutation, and Hepatic Fibrosis in Chronic Hepatitis C. Intervirology, 2009, 52, 239-246.	2.8	13
106	HFE Gene Mutations, Serum Ferritin Level, Transferrin Saturation, and Their Clinical Correlates in a Korean Population. Digestive Diseases and Sciences, 2009, 54, 879-886.	2.3	22
107	A Case of Acute Ischemic Duodenal Ulcer Associated with Superior Mesenteric Artery Dissection After Transarterial Chemoembolization for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2009, 32, 367-370.	2.0	6
108	Genetic analysis of HAV strains isolated from patients with acute hepatitis in Korea, 2005-2006. Journal of Medical Virology, 2008, 80, 777-784.	5.0	39

#	ARTICLE	IF	CITATIONS
109	High prevalence of hepatitis B virus infection in patients with Bâ€cell nonâ€Hodgkin's lymphoma in Korea. Journal of Medical Virology, 2008, 80, 960-966.	5.0	64
110	Hepatitis A in Korea: Epidemiological Shift and Call for Vaccine Strategy. Intervirology, 2008, 51, 70-74.	2.8	55
111	Current Status of Hepatitis C Virus Infection in Korea. Intervirology, 2006, 49, 70-75.	2.8	49